CRISPR Therapeutics AG (CRSP) News
Filter CRSP News Items
CRSP News Results
Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
---|---|---|---|---|---|---|---|---|---|
Loading, please wait... |
CRSP News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest CRSP News From Around the Web
Below are the latest news stories about CRISPR THERAPEUTICS AG that investors may wish to consider to help them evaluate CRSP as an investment opportunity.
3 Mid-Cap Stocks That Could Take Off in 2025Mid-cap stocks represent companies valued at between $2 billion and $10 billion. If they give investors a reason to be bullish on their growth prospects or show that they're on the right path, these types of investments can double in value and be 10-baggers in the long run. Iovance Biotherapeutics has a market cap of $2.3 billion. |
CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15 p.m. PT in San Francisco. A live webcast of the fireside chat will be available on the "Events & Presentations" page in the Investor |
CRISPR Therapeutics AG (CRSP) Registers a Bigger Fall Than the Market: Important Facts to NoteCRISPR Therapeutics AG (CRSP) closed the most recent trading day at $41.92, moving -1.2% from the previous trading session. |
CRISPR Therapeutics Proposes New Appointment to the Board of DirectorsZUG, Switzerland and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be held this year. “We are excited to welcome Briggs to our Board of Directors,” said Samarth Kulkarni, Ph.D., Chief Executive Officer and Chairman of the Board of CR |
Vertex, startup Orna to partner on gene editing researchThe three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia. |
CRISPR Therapeutics AG (CRSP) Increases Despite Market Slip: Here's What You Need to KnowIn the closing of the recent trading day, CRISPR Therapeutics AG (CRSP) stood at $39.36, denoting a +1.84% change from the preceding trading day. |
Why Is CRISPR Therapeutics AG (CRSP) Among the Top CRISPR Stocks to Invest In?We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other CRISPR stocks. The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging […] |
CRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?We recently compiled a list of the 10 Best Gene Therapy Stocks to Buy Right Now. In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against the other gene therapy stocks. Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or […] |
CRISPR Therapeutics AG (CRSP) Advances While Market Declines: Some Information for InvestorsThe latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $41.07, representing a +0.32% change from its previous close. |
Institutional investors may adopt severe steps after CRISPR Therapeutics AG's (NASDAQ:CRSP) latest 8.3% drop adds to a year lossesKey Insights Institutions' substantial holdings in CRISPR Therapeutics implies that they have significant influence... |